Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06549595 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06549595 · ClinicalTrials.gov record · last posted 2026-08-19

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Name: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients — clinical trial record (NCT06549595)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAstraZeneca

Started2024-08-07

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.

Protocol amendment history 5 changes detected by DataLookout

2026-08-20

Trial sites expanded: 224 → 228 locations

2026-07-21

Trial sites expanded: 214 → 224 locations

2026-06-24

Trial sites expanded: 193 → 214 locations

2026-05-21

Trial sites expanded: 159 → 193 locations

2026-04-18

Trial sites expanded: 135 → 159 locations

Trial Details

NCT Number	NCT06549595
Lead Sponsor	AstraZeneca
Conditions	Untreated Follicular Lymphoma
Enrollment	1,018 participants
Start Date	2024-08-07
Primary Completion	2031-11-26 (estimated)
Study Completion	2031-11-26 (estimated)
Updated on ClinicalTrials.gov	2026-08-19